Document Detail

A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy.
MedLine Citation:
PMID:  16010209     Owner:  NLM     Status:  MEDLINE    
Long-term results of high-dose therapy followed by autologous stem cell transplantation (HDT-ASCT) as the first-line treatment for patients with myeloma are still poorly reported. To gain further insight in the long-term benefits of first-line HDT-ASCT compared with conventional therapy in myeloma, we performed a meta-analysis of individual patient data. We selected randomized trials evaluating HDT-ASCT in patients with previously untreated myeloma from 1990 to 1998, all with a median follow-up of 5 years or more. Individual data of the 3 selected trials were obtained from the study authors. Outcomes were survival, treatment-related mortality, and time without symptoms of disease or toxicity of treatment (TWiST). Five hundred seventy-five patients were analyzed, including 435 deaths (104 months of median follow-up). Compared with conventional therapy and adjusting for prognostic covariates, HDT-ASCT did not significantly prolong long-term survival (stratified hazard ratio, 0.887; 95% confidence interval, 0.735-1.072). This was not modified by accounting for heterogeneity in baseline risks, in treatment of relapse, or in outcomes across trials. There was no evidence of interaction between treatment effect on survival and presentation features. In contrast, a mean gain of 14.5 months (95% confidence interval, 9.9-19.1 mo) in TWiST was observed in the HDT-ASCT group compared with conventional therapy. In conclusion, we showed only a trend toward a long-term survival benefit of HDT-ASCT over conventional therapy for first-line treatment of myeloma. However, HDT-ASCT clearly delayed time to relapse, with a resulting 14.5 months benefit in mean TWiST.
Vincent Lévy; Sandrine Katsahian; Jean Paul Fermand; Jean Yves Mary; Sylvie Chevret
Related Documents :
17576909 - Treatment of sudden sensorineural hearing loss: ii. a meta-analysis.
18000649 - Steroid treatment in ards: a critical appraisal of the ards network trial and the recen...
20826029 - A prospective, randomized, multi-center trial to investigate actovegin in prevention an...
2727469 - How study design affects outcomes in comparisons of therapy. ii: surgical.
16186469 - Empirical atypical coverage for inpatients with community-acquired pneumonia: systemati...
11294919 - Phase iii randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
7951279 - Extracorporeal shockwave lithotripsy in anomalous kidneys.
24475439 - Protective effect of selenium on cisplatin induced nephrotoxicity: a double-blind contr...
20479459 - Retropubic versus transobturator midurethral slings for stress incontinence.
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis    
Journal Detail:
Title:  Medicine     Volume:  84     ISSN:  0025-7974     ISO Abbreviation:  Medicine (Baltimore)     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-12     Completed Date:  2005-08-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985248R     Medline TA:  Medicine (Baltimore)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  250-60     Citation Subset:  AIM; IM    
INSERM U 717, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Disease-Free Survival
Follow-Up Studies
Hematopoietic Stem Cell Transplantation* / adverse effects
Longitudinal Studies
Middle Aged
Multicenter Studies as Topic
Multiple Myeloma / drug therapy,  therapy*
Neoplasm Recurrence, Local / physiopathology
Quality of Life
Randomized Controlled Trials as Topic
Survival Rate
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and au...
Next Document:  Improving patient care and quality of life after laryngectomy/glossectomy.